Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.
Richard T. Silver, MD, professor emeritus of Medicine at Weill Cornell Medicine, discusses which patients with myeloproliferative neoplasms (MPNs) may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia (CML) space and in patients with MPNs.
0:08 | It was first used in CML before we had very specific treatment for it. I happen to be very interested in CML, but now, we have much better therapy than interferon, because of the similar for CML because of the similarities of CML to other disease is of the myeloproliferative group.
In 1988, I had the idea of using it in PV and some investigators in Austria have used interferon to treat essential thrombocytopenia [ET]. So, of the 3 MPNs, interferon is most commonly used in PV because many patients with ET do not require therapy at all, when they do interferon is very effective.